Critical shortage of new antibiotics in development against multidrug-resistant bacteria - Time to react is now

Drug Resistance Updates

Volumn 14, Issue 2, 2011, Pages 118-124

  Freire Moran, Laura ^a   Aronsson, Bo ^a   Manz, Chris ^b   Gyssens, Inge C ^c,d   So, Anthony D ^b   Monnet, Dominique L ^e   Cars, Otto ^f,g  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b DUKE UNIVERSITY   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d HASSELT UNIVERSITY   (Belgium)

^e EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^f UPPSALA UNIVERSITY   (Sweden)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibacterial drug development; Antibiotic resistance; Antibiotics; Antimicrobial resistance; ECDC; EMA; Gap analysis; Multidrug resistant bacteria; Novel antimicrobials; ReAct

Indexed keywords

ANTIBIOTIC AGENT; AVIBACTAM; CEFTAROLINE FOSAMIL; CEFTAZIDIME; CEFTOBIPROLE MEDOCARIL; FRIULIMICIN B; HLF1 11; LACTOFERRIN; ME 1036; OPEBACAN; ORITAVANCIN; RAZUPENEM; TALACTOFERRIN; TELAVANCIN; TOMOPENEM; UNCLASSIFIED DRUG; VIQUIDACIN; WAP 8294A2;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; CONFERENCE PAPER; DATA BASE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DATABASES, FACTUAL; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 79955759821     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2011.02.003     Document Type: Conference Paper

References (59)

1. D. Abbanat, B. Morrow, and K. Bush New agents in development for the treatment of bacterial infections Curr. Opin. Pharmacol. 8 2008 582 592
2. Adis, Adis Insight - R&D Insight, retrieved March 14, 2008, from http://adisinsight.com/adis-rdi-int.htm.
3. A. Aliphas, N. Prufer, and K.M. Grundfast Emerging therapies for the treatment and prevention of otitis media Expert. Opin. Emerg. Drugs 11 2006 251 264 (Pubitemid 43723307)
4. A. Amato-Gauci, and A. Ammon The First European Communicable Disease Epidemiological Report 2007 European Centre for Disease Prevention and Control Stockholm, Sweden
5. D.J. Biedenbach, G.J. Moet, and R.N. Jones Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002) Diagn. Microbiol. Infect. Dis. 50 2004 59 69 (Pubitemid 39360263)
6. BioPharm, BioPharm Insight, retrieved March 14, 2008, from http://www.biopharminsight.com/.
7. E.J. Bishop, and B.P. Howden Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions Expert Opin. Emerg. Drugs 12 2007 1 22 (Pubitemid 46499493)
8. B. Blomberg, K.P. Manji, W.K. Urassa, B.S. Tamim, D.S.M. Mwakagile, R. Jureen, V. Msangi, M.G. Tellevik, M. Holberg-Petersen, S. Harthug, S.Y. Maselle, and N. Langeland Antimicrobial resistance predicts death in Tanzanian children with bloodstream infections: a prospective cohort study BMC Infect. Dis. 7 2007 43
9. H.W. Boucher, G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, L.B. Rice, M. Scheld, B. Spellberg, and J. Bartlett Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Clin. Infect. Dis. 48 2009 1 12
10. J.S. Bradley, R. Guidos, S. Baragona, J.G. Bartlett, E. Rubinstein, G.G. Zhanel, M.D. Tino, D.L. Pompliano, F. Tally, P. Tipirneni, G.S. Tillotson, and J.H. Powers Anti-infective research and development: problems, challenges, and solutions Lancet Infect. Dis. 7 2007 68 78 (Pubitemid 44917784)
11. K. Bush, M. Heep, M.J. Macielag, and G.J. Noel Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy Expert Opin. Investig. Drugs 16 2007 419 429 (Pubitemid 46554461)
12. O. Cars, L.D. Hogberg, M. Murray, O. Nordberg, S. Sivaraman, C.S. Lundborg, A.D. So, and G. Tomson Meeting the challenge of antibiotic resistance BMJ 337 2008 a1438
13. G. Cornaglia, A. Lonnroth, and M. Struelens Report from the European Conference on the Role of Research in Combating Antibiotic Resistance, 2003 Clin. Microbiol. Infect. 10 2004 473 497 (Pubitemid 38714581)
14. R.H. Drew Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections Pharmacotherapy 27 2007 227 249 (Pubitemid 46214584)
15. EASAC, 2007. Tackling antibacterial resistance in Europe. London, UK. European Academies Science Advisory Council - The Royal Society. http://www.easac.eu/fileadmin/PDF-s/reports-statements/Tackling.pdf.
16. ECDC/EMEA, 2009. ECDC/EMEA Joint Technical Report: the bacterial challenge: time to react. Stockholm, Sweden. http://www.ecdc.europa.eu/en/ publications/Publications/Forms/ECDC-DispForm.aspx?ID=444.
17. EMA, 2007. Innovative Drug Development Approches. Final report from the EMEA/CHMP-think-tank group on innovative drug development. London, UK. European Medicines Agency. http://www.ema.europa.eu/docs/en-GB/document-library/Other/ 2009/10/WC500004913.pdf.
18. M.E. Falagas, and D.E. Karageorgopoulos Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology Clin. Infect. Dis. 46 2008 1121 1122 author reply 1122 (Pubitemid 351589881)
19. R. Finch, and P.A. Hunter Antibiotic resistance - action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005 J. Antimicrob. Chemother. 58 Suppl. 1 2006 i3 i22
20. French, G.L.; 2008. What's new and not so new on the antimicrobial horizon? Clin. Microbiol. Infect. 14, 19-29. (Pubitemid 352749378)
21. IDSA, 2004. IDSA Report: Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates, a Public Health Crisis Brews. Alexandria (VA), USA. Infectious Diseases Society of America. http://www.idsociety.org/WorkArea/linkit.aspx? LinkIdentifier=id&ItemID=5554.
22. W. Kaplan, and R. Laing Priority Medicines for Europe and the World 2004 WHO Geneva, Switzerland http://archives.who.int/prioritymeds/report/ final18october.pdf
23. I.P. Korbila, and M.E. Falagas Investigational antimicrobial drugs for bloodstream infections Curr. Opin. Investig. Drugs 9 2008 871 878
24. A.L. Kwa, V.H. Tam, and M.E. Falagas Polymyxins: a review of the current status including recent developments Ann. Acad. Med. Singapore 37 2008 870 883
25. J.A. Leeds, E.K. Schmitt, and P. Krastel Recent developments in antibacterial drug discovery: microbe-derived natural products - from collection to the clinic Expert Opin. Investig. Drugs 15 2006 211 226 (Pubitemid 43338143)
26. A. Lepape, and D.L. Monnet Experience of European intensive care physicians with infections due to antibiotic-resistant bacteria Euro Surveill. 14 2009
27. T.S. Lo, J.M. Welch, A.M. Alonto, and E.A. Vicaldo-Alonto A review of the carbapenems in clinical use and clinical trials. Recent Patents Anti-Infect Drug Discov. 3 2008 123 131
28. O. Lomovskaya, H.I. Zgurskaya, M. Totrov, and W.J. Watkins Waltzing transporters and 'the dance macabre' between humans and bacteria Nat. Rev. Drug Discov. 6 2007 56 65 (Pubitemid 46020286)
29. N. Mesaros, P. Nordmann, P. Plesiat, M. Roussel-Delvallez, J. Van Eldere, Y. Glupczynski, Y. Van Laethem, F. Jacobs, P. Lebecque, A. Malfroot, P.M. Tulkens, and F. Van Bambeke Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium Clin. Microbiol. Infect. 13 2007 560 578 (Pubitemid 46730662)
30. P. Moreillon New and emerging treatment of Staphylococcus aureus infections in the hospital setting Clin. Microbiol. Infect. 14 Suppl. 3 2008 32 41
31. C.M. Morel, and E. Mossialos Stoking the antibiotic pipeline BMJ 340 2010 c2115
32. C. Nathan Antibiotics at the crossroads Nature 431 2004 899 902 (Pubitemid 39434399)
33. P. Nordmann, G. Cuzon, and T. Naas The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria Lancet Infect. Dis. 9 2009 228 236
34. S.R. Norrby, C.E. Nord, and R. Finch Lack of development of new antimicrobial drugs: a potential serious threat to public health Lancet Infect. Dis. 5 2005 115 119 (Pubitemid 40174782)
35. A.J. O'Neill New antibacterial agents for treating infections caused by multi-drug resistant Gram-negative bacteria Expert Opin. Investig. Drugs 17 2008 297 302 (Pubitemid 351578182)
36. M.G. Page Emerging cephalosporins Expert Opin. Emerg. Drugs 12 2007 511 524 (Pubitemid 350189121)
37. A. Pan, S. Lorenzotti, and A. Zoncada Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. Recent Patents Anti-Infect Drug Discov. 3 2008 10 33 (Pubitemid 351223212)
38. D.J. Payne, M.N. Gwynn, D.J. Holmes, and D.L. Pompliano Drugs for bad bugs: confronting the challenges of antibacterial discovery Nat. Rev. Drug Discov. 6 2007 29 40 (Pubitemid 46020284)
39. Pharmaprojects, 2008. Pharmaprojects - Pharmaceutical Research & Development Pipeline Intelligence, retrieved March 14, 2008, from www.pharmaprojects.com.
40. G. Poulakou, and H. Giamarellou Investigational treatments for postoperative surgical site infections Expert Opin. Investig. Drugs 16 2007 137 155 (Pubitemid 46206629)
41. S.J. Projan, and P.A. Bradford Late stage antibacterial drugs in the clinical pipeline Curr. Opin. Microbiol. 10 2007 441 446 (Pubitemid 350052689)
42. N. Scheinfeld A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus J. Drugs Dermatol. 6 2007 97 103
43. A.D. So, N. Gupta, S.K. Brahmachari, I. Chopra, B. Munos, C. Nathan, K. Outterson, J.P. Paccaud, D.J. Payne, R.W. Peeling, M. Spigelman, and J. Weigelt Towards new business models for R&D for novel antibiotics Drug Resist. Updat. 14 2011 88 94
44. J.H. Song What's new on the antimicrobial horizon? Int. J. Antimicrob. Agents 32 Suppl. 4 2008 S207 S213
45. M. Souli, I. Galani, and H. Giamarellou Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe Euro Surveill. 13 2008
46. B. Spellberg, J.H. Powers, E.P. Brass, L.G. Miller, and J.E. Edwards Jr. Trends in antimicrobial drug development: implications for the future Clin. Infect. Dis. 38 2004 1279 1286 (Pubitemid 38608571)
47. Swedish Government, 2009. Innovative Incentives for Effective Antibacterials. Stockholm, Sweden. http://www.strama.se/uploads/docs/Innovative Incentives report.pdf.
48. G.H. Talbot What is in the pipeline for Gram-negative pathogens? Expert Rev. Anti Infect. Ther. 6 2008 39 49 (Pubitemid 351372578)
49. G.H. Talbot, J. Bradley, J.E. Edwards Jr.; D. Gilbert, M. Scheld, and J.G. Bartlett Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America Clin. Infect. Dis. 42 2006 657 668 (Pubitemid 43271379)
50. U. Theuretzbacher Future antibiotics scenarios: is the tide starting to turn? Int. J. Antimicrob. Agents 34 2009 15 20
51. U. Theuretzbacher, and J.H. Toney Nature's clarion call of antibacterial resistance: are we listening? Curr. Opin. Investig. Drugs 7 2006 158 166 (Pubitemid 43230912)
52. Tickell, S.; 2005. The Antibiotic Innovation Study: Expert Voices on A Critical Need. Uppsala, Sweden. ReAct - Action on Antibiotic Resistance. http://soapimg.icecube.snowfall.se/stopresistance/AIS%20Report.pdf.
53. F. Van Bambeke, R.R. Reinert, P.C. Appelbaum, P.M. Tulkens, and W.E. Peetermans Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options Drugs 67 2007 2355 2382 (Pubitemid 350071047)
54. P.I. Vergidis, and M.E. Falagas Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options Curr. Opin. Investig. Drugs 9 2008 176 183 (Pubitemid 351206376)
55. M. Vicente, J. Hodgson, O. Massidda, T. Tonjum, B. Henriques-Normark, and E.Z. Ron The fallacies of hope: will we discover new antibiotics to combat pathogenic bacteria in time? FEMS Microbiol. Rev. 30 2006 841 852 (Pubitemid 44583792)
56. White, T.; 2005. Inventory of new antibacterials under development. EU Intergovernmental Conference, 'Antibiotic Resistance: Action to Promote New Technologies', Birmingham, UK.
57. Wong, P.; 2005. Next generation Antibiotics - Combating Drug Resistance. Scrip Report, PharmaprojectsPLUS, T&F Informa Uk Ltd. London, UK.
58. A. Yang, and F.A. Kerdel Infectious disease update: new anti-microbials Semin. Cutan. Med. Surg. 25 2006 94 99 (Pubitemid 44189892)
59. A.K. Zaidi, W.C. Huskins, D. Thaver, Z.A. Bhutta, Z. Abbas, and D.A. Goldmann Hospital-acquired neonatal infections in developing countries Lancet 365 2005 1175 1188 (Pubitemid 40417568)